Retrospective analysis of CD38 expression in 102 patients with B-CLL with a maximum follow-up of 18 years: incidence and prognostic significance.
BACKGROUND
The aim of this study was to evaluate the incidence of CD38 expression in all CLL patients of our institution and to determine its prognostic significance in correlation with other parameters of the disease.


METHODS
We analyzed the CD38 expression in 102 B-CLL patients referred to our department over a period of 12 months.


RESULTS
The follow-up period ranged from 0 to 18 years. 30 patients (29%) were CD38-positive (CD38+) and 72 patients (71%) were CD38-negative (CD38-) with a median age of 65 and 64 years, respectively. Of the Binet A patients (77), 25% showed an expression of CD38; in Binet B/C patients (25), 67% expressed CD38. Median survival of the CD38- group was 77.5 months and of the CD38+ group 56.3 months. CD38 expression was associated with shorter lymphocyte doubling time (p < 0.0001), a more advanced stage of the disease, and a shorter therapy- and progression-free time (p < 0.0017/p < 0.0012), which was also true in the Binet A subgroup. In 2 cases, we detected a shift from the CD38- to the CD38+ phenotype.


CONCLUSIONS
We found a low incidence of CD38+ CLL patients, and CD38 expression predicted significantly a more advanced stage of the disease, shorter lymphocyte doubling time and shorter therapy- and progression-free time.
Jakob
Andreas
A
Medizinische Klinik II, Hämatologie und Onkologie, Klinikum Offenburg, Germany. dr.jakob@gmx.net
Doll
Jasmin
J
Schulte-Mönting
Jürgen
J
Hirsch
Friedrich W
FW
D051997:ADP-ribosyl Cyclase 1 / Q000097:blood*; D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D005858:Germany / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood* / Q000175:diagnosis / Q000401:mortality*; D008297:Male; D011379:Prognosis; D015203:Reproducibility of Results; D012189:Retrospective Studies; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D015996:Survival Rate
D014408:Biomarkers, Tumor; D051997:ADP-ribosyl Cyclase 1